Cinnagen

Iran-based biotechnology company
You can help expand this article with text translated from the corresponding article in Persian. (January 2022) Click [show] for important translation instructions.
  • View a machine-translated version of the Persian article.
  • Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia.
  • Consider adding a topic to this template: there are already 291 articles in the main category, and specifying|topic= will aid in categorization.
  • Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article.
  • You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing Persian Wikipedia article at [[:fa:سیناژن]]; see its history for attribution.
  • You may also add the template {{Translated|fa|سیناژن}} to the talk page.
  • For more guidance, see Wikipedia:Translation.

CinnaGen is an Iran based biotechnology company that was founded in 1994 by four scientists.[specify] As of 2016, it manufactured biosimilar drugs, laboratory diagnostic reagents for in vitro use, and recombinant proteins, and exported to other countries in the Middle East and to countries in the Commonwealth of Independent States.[1]: 70 

Cinnagen logo

One of CinnaGen's products is Cinnovex, a biosimilar of interferon-beta used for treatment of multiple sclerosis; the recombinant DNA used to make the product was created by scientists at Fraunhofer Institute in Germany which also conducted the initial testing; Fraunhofer licensed it to CinnaGen which completed development and obtained approval from Iranian Food and Drug Administration in 2007.[2][3] In a new cooperation agreement, Phases 2 and 3 clinical trials of the Vaxine’s monovalent recombinant COVID-19 vaccine will be initiated in Iran in the coming weeks. If these studies are successful, this Australian vaccine will be produced under the brand name “SpikoGen Archived 2022-07-07 at the Wayback Machine®” by CinnaGen Company and will be rolled out in Iran[4]

See also

References

  1. ^ Science, Technology and Innovation Policy Review: Iran (PDF). United Nations Conference on Trade and Development. 2016.
  2. ^ "Aus Deutschland für Kranke in Iran (From Germany for the sick in Iran)". Wiener Zeitung (in German). 2007-03-20.
  3. ^ "Erstes biogenerisches therapeutisches Protein aus Fraunhofer-Labor für den Markt zugelassen". BioRegio STERN (in German). 2007-01-19. Archived from the original on 2017-10-20. Retrieved 2017-10-20.
  4. ^ ""SpikoGen®", a joint venture between Vaxine and CinnaGen – Vaxine". Archived from the original on 2021-07-11. Retrieved 2021-05-28.

External links

  • CinnaGen official site